Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
RANDOMIZED CONTROLLED TRIAL
Toni K Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Naomi B Haas, Howard Gurney, Piotr Sawrycki, Mauricio Mahave, Marine Gross-Goupil, Tian Zhang, John M Burke, Gurjyot Doshi, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, Stephane Oudard, Delphine Topart, Hans Hammers, Hiroshi Kitamura, David F McDermott, Adriano Silva, Eric Winquist, Jerry Cornell, Aymen Elfiky, Joseph E Burgents, Rodolfo F Perini, Thomas Powles
BACKGROUND: Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results regarding overall survival from the third prespecified interim analysis of the trial would also favor pembrolizumab was uncertain. METHODS: In this phase 3, double-blind, placebo-controlled trial, we randomly assigned (in a 1:1 ratio) participants with clear-cell renal-cell carcinoma who had an increased risk of recurrence after surgery to receive pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks for up to 17 cycles (approximately 1 year) or until recurrence, the occurrence of unacceptable toxic effects, or withdrawal of consent...
April 18, 2024: New England Journal of Medicine
#2
JOURNAL ARTICLE
Yee Peng Phoon, Jared E Lopes, Lukas W Pfannenstiel, Claudia Marcela Diaz-Montero, Ye F Tian, Marc S Ernstoff, Pauline Funchain, Jennifer S Ko, Raymond Winquist, Heather C Losey, Jan Joseph Melenhorst, Brian R Gastman
BACKGROUND: Despite recent advances in immunotherapy, a substantial population of late-stage melanoma patients still fail to achieve sustained clinical benefit. Lack of translational preclinical models continues to be a major challenge in the field of immunotherapy; thus, more optimized translational models could strongly influence clinical trial development. To address this unmet need, we designed a preclinical model reflecting the heterogeneity in melanoma patients' clinical responses that can be used to evaluate novel immunotherapies and synergistic combinatorial treatment strategies...
April 11, 2024: Journal for Immunotherapy of Cancer
#3
JOURNAL ARTICLE
Ryan M Pace, Elana A King-Nakaoka, Andrew G Morse, Kelsey J Pascoe, Anna Winquist, Beatrice Caffé, Alexandra D Navarrete, Kimberly A Lackey, Christina D W Pace, Bethaney D Fehrenkamp, Caroline B Smith, Melanie A Martin, Celestina Barbosa-Leiker, Sylvia H Ley, Mark A McGuire, Courtney L Meehan, Janet E Williams, Michelle K McGuire
BACKGROUND: There is a paucity of data on the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in feces of lactating women with coronavirus disease 2019 (COVID-19) and their breastfed infants as well as associations between fecal shedding and symptomatology. OBJECTIVE: We examined whether and to what extent SARS-CoV-2 is detectable in the feces of lactating women and their breastfed infants following maternal COVID-19 diagnosis. METHODS: This was a longitudinal study carried out from April 2020 to December 2021 involving 57 breastfeeding maternal-infant dyads: 33 dyads were enrolled within 7 d of maternal COVID-19 diagnosis, and 24 healthy dyads served as controls...
2024: Frontiers in Immunology
#4
JOURNAL ARTICLE
Robert J Motzer, Toni K Choueiri, Thomas Hutson, Sun Young Rha, Javier Puente, Aly-Khan A Lalani, Eric Winquist, Masatoshi Eto, Naveen S Basappa, Nizar M Tannir, Ulka Vaishampayan, Georg A Bjarnason, Stéphane Oudard, Viktor Grünwald, Joseph Burgents, Ran Xie, Jodi McKenzie, Thomas Powles
In the phase 3 CLEAR trial, lenvatinib plus pembrolizumab (L + P) showed superior efficacy versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma (aRCC). The combination treatment was associated with a robust objective response rate of 71%. Here we report tumor responses for patients in the L + P arm in CLEAR, with median follow-up of ∼4 yr at the final prespecified overall survival (OS) analysis. Tumor responses were assessed by independent review using Response Evaluation Criteria in Solid Tumors v1...
April 5, 2024: European Urology
#5
JOURNAL ARTICLE
Emanuel Bührer, David D'Haese, Gedske Daugaard, Ronald de Wit, Costantine Albany, Alexey Tryakin, Karim Fizazi, Olof Stahl, Jourik A Gietema, Ugo De Giorgi, Fay H Cafferty, Aaron R Hansen, Torgrim Tandstad, Robert A Huddart, Andrea Necchi, Christopher J Sweeney, Xavier Garcia-Del-Muro, Daniel Y C Heng, Anja Lorch, Michal Chovanec, Eric Winquist, Peter Grimison, Darren R Feldman, Angelika Terbuch, Marcus Hentrich, Carsten Bokemeyer, Helene Negaard, Christian Fankhauser, Jonathan Shamash, David J Vaughn, Cora N Sternberg, Axel Heidenreich, Laurence Collette, Silke Gillessen, Jörg Beyer
AIMS: To resolve the ongoing controversy surrounding the impact of teratoma (TER) in the primary among patients with metastatic testicular non-seminomatous germ-cell tumours (NSGCT). PATIENTS AND METHODS: Using the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium database, we compared the survival probabilities of patients with metastatic testicular GCT with TER (TER) or without TER (NTER) in their primaries corrected for known prognostic factors...
March 30, 2024: European Journal of Cancer
#6
JOURNAL ARTICLE
Heather Demorest, Rachel Hinnenkamp, Maggie Cook-Shimanek, Alyssa N Troeschel, Michael Yeh, Thao-Phuong Christy Hallett, David Kuai, Johnni Daniel, Andrea Winquist
During March-April 2023, a total of 51 persons reported mild to severe gastrointestinal illness after eating at restaurant A in Bozeman, Montana. The outbreak resulted in multiple severe outcomes, including three hospitalizations and two deaths. After an inspection and temporary restaurant closure, the Montana Department of Public Health and Human Services and Montana's Gallatin City-County Health Department collaborated with CDC to conduct a matched case-control study among restaurant patrons to help identify the source of the outbreak...
March 14, 2024: MMWR. Morbidity and Mortality Weekly Report
#7
JOURNAL ARTICLE
Morgan D Black, John Yoo, Kevin Fung, Danielle MacNeil, David A Palma, Joseph S Mymryk, Sara Kuruvilla, John W Barrett, Eric Winquist, Anthony C Nichols
Recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC) is associated with a poor prognosis and short survival duration. There is an urgent need to identify personalized predictors of drug response to guide the selection of the most effective therapy for each individual recurrence. We tested the feasibility of patient-derived xenografts (PDX) for guiding their RMHNSCC salvage treatment. Fresh tumor samples from eligible, consented patients were implanted into mice. Established tumors were expanded in mouse PDX cohorts to identify responses to candidate salvage drug treatments in parallel testing...
February 2024: Curēus
#8
JOURNAL ARTICLE
O Sheehy, S Eltonsy, S Hawken, M Walker, P Kaul, B Winquist, O Barrett, A Savu, R Dragan, M Pugliese, S Bernatsky, J Gorgui, A Bérard
Health Canada (HC) has, since 2013, issued safety alerts restricting the use of codeine-containing drugs among breastfeeding women and children/adolescents under 18 years of age. These products are linked to breathing problems among ultra-rapid CYP2D6 metabolizers and early use of opioid can lead to future opioid misuse. Using a multi-province population-based cohort study, we estimate the impact of federal safety alerts on annual rates of codeine use in the Canadian pediatric population. We analyzed data from 8,156,948 children/adolescents in five Canadian provinces between 1996 and 2021, using a common protocol...
March 4, 2024: Scientific Reports
#9
JOURNAL ARTICLE
Peter Y F Zeng, Stephenie D Prokopec, Stephen Y Lai, Nicole Pinto, Michelle A Chan-Seng-Yue, Roderick Clifton-Bligh, Michelle D Williams, Christopher J Howlett, Paul Plantinga, Matthew J Cecchini, Alfred K Lam, Iram Siddiqui, Jianxin Wang, Ren X Sun, John D Watson, Reju Korah, Tobias Carling, Nishant Agrawal, Nicole Cipriani, Douglas Ball, Barry Nelkin, Lisa M Rooper, Justin A Bishop, Cathie Garnis, Ken Berean, Norman G Nicolson, Paul Weinberger, Ying C Henderson, Christopher M Lalansingh, Mao Tian, Takafumi N Yamaguchi, Julie Livingstone, Adriana Salcedo, Krupal Patel, Frederick Vizeacoumar, Alessandro Datti, Liu Xi, Yuri E Nikiforov, Robert Smallridge, John A Copland, Laura A Marlow, Martin D Hyrcza, Leigh Delbridge, Stan Sidhu, Mark Sywak, Bruce Robinson, Kevin Fung, Farhad Ghasemi, Keith Kwan, S Danielle MacNeil, Adrian Mendez, David A Palma, Mohammed I Khan, Mushfiq Shaikh, Kara M Ruicci, Bret Wehrli, Eric Winquist, John Yoo, Joe S Mymryk, James W Rocco, David Wheeler, Steve Scherer, Thomas J Giordano, John W Barrett, William C Faquin, Anthony J Gill, Gary Clayman, Paul C Boutros, Anthony C Nichols
Anaplastic thyroid carcinoma is arguably the most lethal human malignancy. It often co-occurs with differentiated thyroid cancers, yet the molecular origins of its aggressivity are unknown. We sequenced tumor DNA from 329 regions of thyroid cancer, including 213 from patients with primary anaplastic thyroid carcinomas. We also whole genome sequenced 9 patients using multi-region sequencing of both differentiated and anaplastic thyroid cancer components. Using these data, we demonstrate thatanaplastic thyroid carcinomas have a higher burden of mutations than other thyroid cancers, with distinct mutational signatures and molecular subtypes...
February 26, 2024: Cell Reports
#10
JOURNAL ARTICLE
Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Boris Alekseev, Sun Young Rha, Jaime Merchan, Jeffrey C Goh, Aly-Khan A Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung-Hoo Hong, Howard Gurney, María José Méndez-Vidal, Evgeny Kopyltsov, Sergei Tjulandin, Teresa Alonso Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph Burgents, Cixin He, Chinyere E Okpara, Jodi McKenzie, Toni K Choueiri
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We present the final prespecified overall survival (OS) analysis of the open-label, phase III CLEAR study in treatment-naïve patients with advanced renal cell carcinoma (aRCC)...
January 16, 2024: Journal of Clinical Oncology
#11
JOURNAL ARTICLE
Ghady Bou-Nehme Sawaya, Alice Dragomir, Lori A Wood, Christian Kollmannsberger, Naveen S Basappa, Anil Kapoor, Denis Soulières, Antonio Finelli, Daniel Y C Heng, Vincent Castonguay, Christina Canil, Eric Winquist, Jeffrey Graham, Georg A Bjarnason, Bimal Bhindi, Aly-Khan Lalani, Frédéric Pouliot, Rodney H Breau, Ramy Saleh, Simon Tanguay
BACKGROUND AND OBJECTIVE: Metastatic renal cell carcinoma (mRCC) patients have been reported to have better outcomes when treated with immunotherapies (IO) compared to targeted therapies (TT). This study aims to evaluate the impact of first-line systemic therapies on survival of mRCC patients with or without sarcomatoid features using real-world data. METHODS: Metastatic RCC patients of International mRCC Database Consortium (IMDC) intermediate or high risk, diagnosed from January 2011 to December 2022, treated with first-line systemic therapies, and with histological documentation of the presence or absence of sarcomatoid features in nephrectomy specimens were identified using the Canadian Kidney Cancer information system...
December 13, 2023: European Urology Oncology
#12
JOURNAL ARTICLE
Andrea Winquist, James M Hodge, W Ryan Diver, Juan L Rodriguez, Alyssa N Troeschel, Johnni Daniel, Lauren R Teras
BACKGROUND: Previous epidemiological studies found associations between exposure to per- and polyfluoroalkyl substances (PFAS) and some cancer types. Many studies considered highly exposed populations, so relevance to less-exposed populations can be uncertain. Additionally, many studies considered only cancer site, not histology. OBJECTIVES: We conducted a case-cohort study within the American Cancer Society's prospective Cancer Prevention Study II (CPS-II) LifeLink cohort to examine associations between PFAS exposure and risk of selected cancers, considering histologic subtypes...
December 2023: Environmental Health Perspectives
#13
Zahra Taboun, Peter Zeng, Jasna Deluce, Kevin Fung, John Barrett, Lama Elkadri, David Palma, Paul Stewart, Matthew J Cecchini, Anthony Nichols, Eric Winquist
Laryngeal cancer most frequently develops in males aged 60-70 years with a history of tobacco and/or alcohol use, while fewer cases occur in young patients in which tobacco and alcohol are often absent or less significant, highlighting the importance of other etiologies. We present cases of human papillomavirus (HPV)-associated laryngeal cancer in two previously healthy young women. A retrospective case review was carried out for both patients. DNA was extracted from the primary tumors and matched to normal tissue or blood, HPV genotype was determined by PCR and whole exome sequencing was carried out...
November 2023: Curēus
#14
Wei Cen Wang, Beatrice Preti, Nancy Read, Paul Gibson, Keith Kwan, Eric Winquist
BACKGROUND: Epstein-Barr virus (EBV)-related nasopharyngeal cancer (NPC) is a common type of cancer in certain areas of the world such as southeast Asia, but is uncommon in Canada. There is currently no reliably effective standard treatment for incurable metastatic EBV-related NPC that progresses after first-line therapy with gemcitabine/cisplatin. METHODS: With his consent, the health records of a patient with relapsed metastatic EBV-related NPC treated with pembrolizumab immunotherapy were retrospectively reviewed and reported...
2023: Frontiers in Oncology
#15
JOURNAL ARTICLE
Anna Winquist, Celestina Barbosa Leiker, Tullamora Landis, Jennifer Fraser, Linda L Eddy, Ekaterina Burduli
PURPOSE: In the United States (US), nurses have a mandated duty to report child abuse and neglect (CAN). Despite comprising the highest proportion of the US healthcare workforce, limited research has explored the institutional barriers they face in reporting suspected CAN. Furthermore, there is no existing valid and reliable measure of reporting relevant to US. The purpose of this research is to develop and psychometrically evaluate a scale to measure nurse knowledge and self-efficacy as CAN mandated reporters...
October 18, 2023: Journal of Pediatric Nursing
#16
RANDOMIZED CONTROLLED TRIAL
E Hjalmarsson, L Hellkvist, A Karlsson, O Winquist, S Kumlien Georén, U Westin, L O Cardell
BACKGROUND: Intralymphatic immunotherapy (ILIT) is a novel, faster alternative to conventional allergen immunotherapy (AIT). Few previous studies have evaluated its long-term effects. The objective of the present study was to complete a 5-year follow-up of a randomized double-blind placebo-controlled trial of ILIT for a combination of birch and grass allergens. METHODS: Fifty-eight patients with allergic rhinitis were treated with either placebo or a combination of ALK Alutard Birch and Grass 1000 SQ-U administered in 3 intralymphatic injections at 1-month intervals...
October 2023: Journal of Investigational Allergology & Clinical Immunology
#17
JOURNAL ARTICLE
V S Tan, A Warner, A Nichols, E Winquist, D A Palma
PURPOSE/OBJECTIVE(S): The objective of this study was to determine the impact of the COVID-19 pandemic on academic productivity in oncology as measured by conference abstracts, journal publications and individual authorship trends. MATERIALS/METHODS: Using a reference time frame of 2018 to 2022, we obtained data on the number of abstracts and articles submitted and published from a selection of oncology conferences and journals. To assess individual authorship patterns, we randomly selected 200 articles from 2018 (i...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
#18
JOURNAL ARTICLE
Jakob Lauritsen, Nicolas Sauvé, Alexey Tryakin, Di Maria Jiang, Robert Huddart, Daniel Y C Heng, Angelika Terbuch, Eric Winquist, Michal Chovanec, Marcus Hentrich, Christian D Fankhauser, Jonathan Shamash, Xavier Garcia Del Muro, David Vaughn, Axel Heidenreich, Cora N Sternberg, Christopher Sweeney, Andrea Necchi, Carsten Bokemeyer, Mikkel Bandak, Abolghassem Jandari, Laurence Collette, Silke Gillessen, Joerg Beyer, Gedske Daugaard
BACKGROUND: Active surveillance after orchiectomy is the preferred management in clinical stage I (CSI) germ-cell tumours (GCT) associated with a 15 to 30% relapse rate. PATIENTS AND METHODS: In the IGCCCG Update database, we compared the outcomes of gonadal disseminated GCT relapsing from initial CSI to outcomes of patients with de novo metastatic GCT. RESULTS: A total of 1014 seminoma (Sem) [298 (29.4%) relapsed from CSI, 716 (70.6%) de novo] and 3103 non-seminoma (NSem) [626 (20...
September 30, 2023: British Journal of Cancer
#19
JOURNAL ARTICLE
Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E Burgents, Rodolfo Perini, Cixin He, Chinyere E Okpara, Jodi McKenzie, Toni K Choueiri
INTRODUCTION: The phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features including presence and/or site of baseline metastases, prior nephrectomy, and sarcomatoid features have been associated with disease and treatment success. This subsequent analysis explores outcomes in patients with or without specific prognostic features...
2023: Frontiers in Oncology
#20
JOURNAL ARTICLE
Angela R Korabik, Tallulah Winquist, Edwin D Grosholz, Jordan A Hollarsmith
Climate change is affecting marine ecosystems in many ways, including raising temperatures and leading to ocean acidification. From 2014 to 2016, an extensive marine heat wave extended along the west coast of North America and had devastating effects on numerous species, including bull kelp (Nereocystis luetkeana). Bull kelp is an important foundation species in coastal ecosystems and can be affected by marine heat waves and ocean acidification; however, the impacts have not been investigated on sensitive early life stages...
August 4, 2023: Journal of Phycology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
